土耳其2018-21年抗生素耐药性调查:基于CLSI、EUCAST和PK/PD折点
该研究测定了土耳其四家医院2018-21年社区获得性呼吸道感染分离的肺炎链球菌(n=142)和流感嗜血杆菌(n=315)的MIC,并用CLSI、EUCAST及PK/PD折点判读敏感性。肺炎链球菌对氟喹诺酮类敏感性≥97.9%,对青霉素敏感性按不同折点为35.9%-82.4%;流感嗜血杆菌对多数抗生素敏感性>90%,但氨苄西林(85.4%)和复方磺胺甲噁唑(64.1%)较低。
要点
- 肺炎链球菌对氟喹诺酮类高度敏感,对青霉素敏感性因折点而异。
- 流感嗜血杆菌对多数抗生素敏感率>90%,但复方磺胺甲噁唑仅64.1%。
- 折点选择显著影响药敏判读,如口服头孢呋辛EUCAST为0%、CLSI为99.4%。
核心结论
- 肺炎链球菌除氟喹诺酮类、阿莫西林、阿莫西林/克拉维酸、头孢噻肟和头孢曲松外,敏感性<60%。
- 流感嗜血杆菌对多数抗生素敏感性>90%,但复方磺胺甲噁唑和氨苄西林较低。
研究设计与样本
- 研究纳入土耳其四家医院2018-21年社区获得性呼吸道感染分离的肺炎链球菌(n=142)和流感嗜血杆菌(n=315)。
- 采用CLSI方法测定MIC,并用CLSI、EUCAST及PK/PD折点判读敏感性。
主要发现
- 肺炎链球菌对青霉素敏感性按CLSI口服/EUCAST低剂量折点为35.9%,按EUCAST高剂量/CLSI静脉折点为82.4%。
- 肺炎链球菌对头孢曲松、阿莫西林/克拉维酸、阿莫西林和头孢噻肟敏感性为78.2%-82.4%(CLSI)。
- 肺炎链球菌对其他头孢菌素、四环素类、大环内酯类和复方磺胺甲噁唑敏感性较低(42.3%-59.2%),氟喹诺酮类≥97.9%。
- 流感嗜血杆菌中β-内酰胺酶阴性294株(93.3%),β-内酰胺酶阴性氨苄西林耐药按EUCAST为26株(8.3%)、按CLSI为8株(2.5%)。
- 流感嗜血杆菌对多数抗生素敏感性≥91.8%(CLSI),但氨苄西林85.4%、复方磺胺甲噁唑64.1%。
关键数值与推荐
- 肺炎链球菌对青霉素敏感性:CLSI口服/EUCAST低剂量折点35.9%,EUCAST高剂量/CLSI静脉折点82.4%。
- 肺炎链球菌对高剂量阿莫西林EUCAST敏感性64.8%,高剂量阿莫西林/克拉维酸59.2%,头孢克洛0%,高剂量头孢曲松99.3%。
- 肺炎链球菌对阿莫西林和阿莫西林/克拉维酸的高剂量PK/PD折点敏感性分别为87.3%和88.0%。
- 流感嗜血杆菌对口服头孢呋辛敏感性:EUCAST 0%、PK/PD 71.7%、CLSI 99.4%;对大环内酯类:无EUCAST折点,PK/PD 1.0%-2.5%,CLSI 96.5%-99.1%。
临床怎么用
- 临床判读肺炎链球菌药敏时需注意折点选择,青霉素敏感性因折点不同差异显著。
- 流感嗜血杆菌经验性治疗应避免复方磺胺甲噁唑,氨苄西林敏感性也需关注。
- 对口服头孢呋辛和大环内酯类,EUCAST与CLSI判读差异大,应结合本地折点标准。
局限性
- 研究仅纳入土耳其四家医院,样本量有限,代表性可能受限。
- 未报告患者临床结局与治疗相关性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the antibiotic susceptibility of Streptococcus pneumoniae and Haemophilus influenzae from community-acquired respiratory tract infections from four hospitals in Türkiye in 2018-21. METHODS: MICs were determined by CLSI methodology, and susceptibility was interpreted using CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. RESULTS: S. pneumoniae (n = 142) and H. influenzae (n = 315) isolates were collected. Penicillin susceptibility in pneumococci was 35.9% by CLSI oral/EUCAST low-dose breakpoints and 82.4% by EUCAST high-dose/CLSI intravenous administration. Similar susceptibility (78.2%-82.4%, CLSI) was observed for ceftriaxone, amoxicillin/clavulanic acid, amoxicillin and cefotaxime. Other cephalosporins, tetracyclines, macrolides and trimethoprim/sulfamethoxazole were poorly active (42.3%-59.2%); fluoroquinolones (≥97.9%) were most active. Susceptibility by EUCAST was lower for high-dose amoxicillin (64.8%), high-dose amoxicillin/clavulanic acid (59.2%) and cefaclor (0%), but higher for high-dose ceftriaxone (99.3%). High-dose PK/PD breakpoints for amoxicillin and amoxicillin/clavulanic acid increased susceptibility (87.3% and 88.0%). Most H. influenzae were β-lactamase negative (n = 294, 93.3%); 26 (8.3%) were β-lactamase-negative ampicillin-resistant by EUCAST breakpoints and eight (2.5%) by CLSI breakpoints. Antibiotic susceptibility was ≥91.8% (CLSI) except ampicillin (85.4%) and trimethoprim/sulfamethoxazole (64.1%). EUCAST or PK/PD breakpoint susceptibility was similar, except for oral cefuroxime (0% EUCAST, 71.7% PK/PD and 99.4% CLSI) and macrolides (no EUCAST breakpoint, 1.0%-2.5% PK/PD and 96.5%-99.1% CLSI). CONCLUSIONS: Susceptibility in S. pneumoniae was <60% except for fluoroquinolones, amoxicillin and amoxicillin/clavulanic acid, cefotaxime and ceftriaxone. H. influenzae susceptibility to most antibiotics was >90% except for trimethoprim/sulfamethoxazole and ampicillin. These data are similar to recent surveillance of antibiotic resistance data in Türkiye.
引用
- Torumkuney D, Keles N, Hasdemir U, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Türkiye: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother. 2025. PMID: 41277341. doi:10.1093/jac/dkaf289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。